Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant.

Gynecologic oncology - 1 Oct 2025

Apostol Adriana I, Kotsopoulos Joanne, Gronwald Jacek, Kim Raymond H, Karlan Beth Y, Aeilts Amber, Cajal Teresa Ramón Y, Pal Tuya, Eisen Andrea, Bordeleau Louise, Foulkes William D, Couch Fergus, Zakalik Dana, Fruscio Robert, Sun Ping, Lubinski Jan, Tung Nadine, Singer Christian F, Moller Pal, Dominguez-Valentin Mev, Narod Steven A, Metcalfe Kelly

Abstract excerpt

OBJECTIVE: Inherited BRCA1/2 pathogenic variants (mutations) confer high lifetime risks of breast and ovarian cancers. Estimating the cumulative ovarian cancer risk following a breast cancer diagnosis in these women will help guide decisions regarding preventive salpingo-oophorectomy. METHODS: Women carrying a BRCA1 or BRCA2 mutation were followed after breast cancer and completed follow-up questionnaires every...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fallopian Tube Neoplasms

Share to Follow-Up Studies

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Ovarian Neoplasms

Share to Salpingo-oophorectomy

Source

Identifiers

PMID: 40784323
DOI: 10.1016/j.ygyno.2025.07.030

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant.PMID 40784323Read ↗

Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2.Semantic proximity Read ↗

The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.Semantic proximity Read ↗

Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

Managing hereditary breast cancer risk in women with and without ovarian cancer.Semantic proximity Read ↗

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.Semantic proximity Read ↗

The contribution of BRCA1 and BRCA2 to ovarian cancer.Semantic proximity Read ↗

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.Semantic proximity Read ↗

Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy.Semantic proximity Read ↗

[Clinical and familial characterisation of ovarian cancer patients with germline mutations in the BRCA1/2 gene and the current status of prevention in high-risk groups].Semantic proximity Read ↗

Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.Semantic proximity Read ↗

Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.